Like so many innovations, the ideas that launched SelSym Biotech emerged over a few cups of coffee and some furious scribbling on napkins. Those conversations led to a remarkable collaboration between ambitious scientists, engineers, and clinicians – all of whom were driven to address the key unmet clinical needs in trauma and hemorrhage treatment and management.
Now more than a decade later, those ideas have become the foundation of SymClot, SelSym’s innovative platelet-mimetic technology, which holds tremendous promise in transforming the care of traumatic injury and post-surgical bleeding. SymClot addresses vital needs and closes critical gaps in current hemostasis technologies, including:
TRAUMA
Emergency stabilization of hemorrhage improves patient survival following trauma
HOSPITAL
Cost-effective therapy that supports reactive OR proactive treatment for surgical bleeding
HEALING
Unique mechanism of action supports and improves overall wound healing outcomes after cessation of bleeding
SAFETY
Wound-targeting technology minimizes risk of immune or thrombotic complications
SUPPLY CHAIN
Fast scale-up and easy storage & transport to address critical platelet shortages
SymClot: A Novel Therapy to Control Bleeding
SelSym Biotech’s lead product, SymClot, mimics platelet functions to augment hemorrhage control in trauma and surgery and helps to address critical ongoing platelet supply shortages and shelf life limitations
Hemostatic Healing Hydrogels (H3)
SelSym Biotech’s suite of Hemostatic Healing Hydrogels (H3) can be easily tuned to address a wide range of clinical needs in bleeding management and wound healing, including hemorrhage control, drug delivery, infection control, and long-term healing support for chronic wounds